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The cell surface expression of CD9, a glycoprotein of the
tetraspanin family influencing several processes including cell
motility and metastasis, inversely correlates with progression
in several solid tumors. In the present work, we studied the
expression and role of CD9 in multiple myeloma (MM) biology
using the 5T33MM mouse model. The 5T33MMvitro cells were
found to be CD9 negative. Injection of these cells in mice
caused upregulation of CD9 expression, while reculturing them
resulted in downregulation of CD9. Coculturing of CD9-negative
5T33MMvitro cells with BM endothelial cells (BMECs) resulted
in a partial retrieval of CD9. Laser microdissection followed by
real-time polymerase chain reaction and immunohistochemis-
try performed on bone sections of 5T33MMvivo diseased mice
demonstrated strong local expression of CD9 on MM cells in
contact with BMEC compared to MM cells further away. These
findings were also confirmed by immunohistochemistry in MM
patients. Neutralizing anti-CD9 antibodies inhibited transen-
dothelial invasion of CD9-expressing human MM5.1 and murine
5T33MMvivo cells. In conclusion, we provide evidence that CD9
expression by the MM cells is upregulated in vivo by close
interaction of the cells with BMEC and that CD9 is involved in
transendothelial invasion, thus possibly mediating homing and/
or spreading of the MM cells.
Leukemia (2006) 20, 1870–1879. doi:10.1038/sj.leu.2404343;
published online 10 August 2006
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Introduction
Multiple myeloma (MM) is an incurable plasma cell malignancy
characterized by an uncontrolled expansion and accumulation
of monoclonal plasma cells (PCs) in the bone marrow (BM),
secretion of paraprotein in the serum, development of osteolytic
bone lesions and angiogenesis in the BM. The malignant cells
depend on the BM microenvironment for their survival and
growth and are therefore selectively localized in this tissue.
Only in late disease stages, myeloma cells become independent
of their microenvironment, resulting in extramedullary growth.1–4
Given that the origin of the myeloma cells is post-germinal, their
specific localization in the BM during the main course of the
disease evolution implies migration from the vascular to the
extravascular compartment of the BM.5 This migration is
referred to as homing. A model described by Butcher and
Picker6 represents the trafficking and homing of lymphocytes as
a multistep process involving reversible rolling on the blood
vessel wall, activation-dependent arrest and subsequent trans-
endothelial migration. In analogy to the homing of lymphocytes,
one can assume that the homing of myeloma cells is also such a
multistep process.
CD9 is a cell surface glycoprotein belonging to the tetraspanin
family. Tetraspanins constitute a family of over 30 membrane
glycoproteins with four hydrophobic transmembrane domains.
Most tetraspanins, except for CD53 and CD37, are broadly
expressed. It has been suggested that they serve as adaptor
molecules and they interact with numerous proteins including
other members of the tetraspanin family, different types of
receptors, proteins with Immunoglobulin (Ig) domains, integrins
and major histocompatibility complex molecules. Most of the
natural ligands are still unknown.7–11 It has been reported that
tetraspanins can influence several biological and pathological
processes, including cell motility and metastasis, adhesion, cell
proliferation, differentiation, fusion, cellular signaling, cyto-
skeletal reorganization and virus infection.11,12 Moreover, the
expression of many members of the family is altered in different
types of carcinomas.13,14 In particular, the inverse correlation
between the CD9 expression levels and tumor progression and
metastasis in several solid tumors, including melanoma,15
breast,16 lung,17 colon18 and ovarian cancer,19 suggests that
low CD9 expression might be one of the steps favoring cancer
progression. Moreover, transfection of CD9 cDNA resulted in
the suppression of motility and metastasis, suggesting that CD9
downregulation might be associated with highly metastatic
behavior of the tumor cells.20,21 However, recent reports are
questioning this hypothesis: in human osteosarcoma22 and in
breast cancer,23 CD9 expression levels did not provide useful
prognostic information. Moreover, a study showed that in
cervical carcinomas, CD9 is indeed globally downregulated in
most invasive cervical carcinomas, but re-expressed in cells
close to vessels and in the process of transendothelial transi-
tion.24 These findings indicate that the role of CD9 in cancer
progression is very complex.
Until now, little is known about the expression and role of
CD9 and tetraspanins in general in the MM cell biology and
disease progression. In the early 1990s, Ikeyama et al.20
demonstrated suppression of cell motility after introduction of
CD9 cDNA in the CD9-negative, highly motile, Epstein–Barr
virus (EBV)-transformed human cell line ARH77. Recently,
surface expression of several tetraspanin antigens (among which
CD9) was investigated in a small number of newly diagnosed,
untreated monoclonal gammopathy of undetermined signifi-
cance (MGUS) (n¼ 5) and MM (n¼ 5) patients. Clonal PC from
MM patients showed significant reduced CD9 expression as
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compared to PC from MGUS patients and to their normal
counterparts.25 Screening of human myeloma cell lines (n¼ 6)
for tetraspanin expression by flow cytometry revealed the
predominant absence of CD9, CD81 and CD82. This absence
was characterized by reduced steady-state mRNA levels and
methylation of the promoter regions. Re-expression of these
tetraspanins both at mRNA and protein level following de-
methylation supported functional contribution of the hyper-
methylation to regulating transcription of CD9 protein.26
In the present study, we used the 5T33MM experimental
mouse model and the human myeloma cell line MM5.1 to
investigate the expression and role of CD9 in MM. The 5T33MM
mouse model is a suitable model to study the development of
MM. The 5TMM cell lines originated spontaneously in elderly
C57Bl/KaLwRij mice and have since been propagated in
syngeneic, young mice by transplantation of diseased BM cells
isolated from MM-bearing mice.27 By this method, several
exclusively in vivo growing MM cell lines were obtained. The
clinical and molecular characteristics of these models are very
similar to those of the human disease.4,28
The cellular expression of CD9 was analyzed both before and
after in vivo passage followed by cultivating with or without BM
endothelial cells (BMECs). Differential expression in the myelo-
ma cells near BMEC or positioned at a distance from the BMEC
was assessed in situ with laser microdissection (LMD) combined
with quantitative real-time polymerase chain reaction (PCR)
analysis. In addition, immunostainings for CD9 were performed
on bone sections from both 5T33MM mice and untreated newly
diagnosed MM patients. Finally, the possible role of CD9 in
transendothelial invasion of the myeloma cells was evaluated.
Materials and methods
Mice
C57Bl/KaLwRij mice were purchased from Harlan CPB (Horst,
The Netherlands). Mice were used at 8–10 weeks of age and
housed and treated following the conditions approved by the
Ethical Committee for Animal Experiments, VUB (License no.
LA1230281).
Cell lines
The 5T33MMvv cell line originated from elderly C57Bl/KaLwRij
mice that spontaneously developed MM. The cells have since
been propagated into syngeneic, young mice by transplantation
of diseased BM cells. Mice were either killed when clear signs of
paralysis of the hind legs were observed (terminally diseased
mice, 28 days) or at day 13 after intravenous (i.v.) injection of
the tumor cells, a time point when they are first detectable by
flow cytometry (intermediate stage, tumor load between 5 and
20%).29,30 Isolation and purification of the myeloma cells in the
BM was performed as described previously.31
The murine 5T33MMvt cell line is a clonally identical, but in
vitro stroma-independent growing variant of the 5T33MMvv cell
line. Cells were cultured and maintained in Rosewell Park
Memorial Institute (RPMI)-1640 medium (BioWhittaker, Ver-
viers, Belgium) supplemented with 10% fetal calf serum (FCS)
(Fetal clone I; Hyclone, Logan, UT, USA), 1% natriumpyruvate,
100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine
and 1% minimum essential medium (supplements from Bio-
Whittaker). These cells are also able to induce MM, when i.v.
injected in syngeneic, young mice. The take time of this
5T33MMvtvv model is 10 weeks. Mice were either killed when
a serum paraprotein concentration of 10 mg/ml was reached
(terminally diseased mice, 10 weeks) or 4–5 weeks after i.v.
injection of the myeloma cells when they are detectable by flow
cytometry (early stages, tumor load between 5 and 15%).
Isolation and purification of the myeloma cells in the BM was
performed as described previously.31
The murine BM sinusoidal endothelial cell line STR4 was
originally established by transfecting primary endothelial cell
cultures with SV40 and was cultured in RPMI-1640 medium
supplemented as described above.32
The well-characterized human stroma-dependent MM5.1 and
stroma-independent MM5.2 MM cell lines were selected for our
experiments. Cells were kept in culture as described previously.33
The human BM endothelial cell line 4LHBMEC (kindly
provided by Dr A Dra¨ger, Department of Hematology, Free
University Amsterdam, The Netherlands) was cultured in 10%
FCS-199 medium (International Medical, Brussels, Belgium) with
10 ng/ml endothelial cell growth factor (ECGF) (Roche, Brussels,
Belgium) until a confluent adherent cell layer was obtained.
Cells were recovered for further use after trypsinization.
Cocultures of BM endothelial cells with 5T33MMvt and
vtvvvt cells
STR4 cells (0.5 106) were seeded in 25 cm2 flasks (BD Falcon,
Mountain View, CA, USA) in complete growth medium. After
24 h, cells were washed twice with serum-free medium and
cultured with 5T33MMvt or 5T33MMvtvvvt cells (1 106 cells)
in 6 ml RPMI-1640 medium with 5% fetal clone I (FCI) and
supplements for 5 days.
Flow cytometry
CD9 cell membrane expression on the 5T33MM myeloma cells
during disease progression was detected by a double-staining
procedure. The rat anti-mouse antibody (KMC8) was used as
primary antibody (BD, Mountain View, CA, USA) and fluor-
escein isothiocyanate (FITC)-conjugated goat anti-rat Ig G
monoclonal antibody was used as a second step (Oxford
Biotechnology, Oxfordshire, UK). An isotype-matched irrelevant
antibody was used as control. The proportion of tumor cells was
determined by staining the cells with a tumor-specific anti-
idiotype monoclonal antibody as described previously.34 Cells
were analyzed with a FACSCanto flow cytometer (BD) using
CellQuest and FACS Diva software.
LMD and pressure catapulting microscopy
The hind limbs were dissected from 5T33MMvv terminally
diseased mice and directly freeze embedded in OCT compound
(Optimal Cutting Temperature; Tissue-TEK from Sakura Finetek,
Zoeterwoude, The Netherlands) by cooling in liquid nitrogen.
To prevent RNA degradation within the bones, the time between
the death of the mouse and freezing the bones down to 801C
was kept below 5 min. Five-micrometer-thick sections were cut
on the Cryo-microtome (Bright, OTF5000, Cambridgeshire, UK)
combined with a CryoJane system (Instrumedics, St Louis, MO,
USA). The sections were fixed in acetone for 3 min at 41C and
subsequently incubated for 90 s at 41C with FITC-labeled rat
anti-mouse CD31 (BD) antibodies diluted 1:5 in phosphate-
buffered saline (PBS). Finally, the sections were quickly rinsed in
PBS, dehydrated in series of ethanol and kept in 99% ethanol
during the selection of cells for dissection. The slide was then
positioned in a computer-assisted laser microdissecting and
pressure-catapulting microscope (PALM laser technology, Bern-
ried, Germany) equipped for fluorescence microscopy. Three
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areas were selected: CD31-positive BMECs, myeloma cells
adjacent to the BMEC and myeloma cells away from the BMEC.
As preliminary immunohistochemical evaluations of adjacent
cryosections using the CD31 binding antibody and a tumor-
specific anti-idiotype monoclonal antibody revealed the marrow
to be packed with tumor cells, we assumed and confirmed by
quantitative PCR (Q-PCR) that the dissected cells adjacent and
away from the EC were essentially myeloma cells. The selected
and dissected areas where sequentially catapulted into a cap
containing 35 ml extraction buffer (Picopure, Arcturus, Mountain
View, CA, USA) and the RNA was purified from the dissected
cells as described by the manufacturer (Arcturus).
The quality of the RNA was assessed using the Experion
system from Biorad (Hercules, CA, USA). Its principle is based
on the quantification of the 18S/28S ratios. Ratios close to 2
were defined as high-quality RNA. Only specimens with such
ratios were included in our analysis.
Quantitative real-time PCR
The RNA obtained from the laser microdissections was
converted into cDNA using the Iscript first-strand synthesis
system (Biorad) using random hexamer primers. Reference RNA
samples with 1, 5 and 25 mg of RNA purified from full sections of
diseased 5T33MM bones were converted into cDNA together
with the laser dissected samples. Real-time Q-PCR was
performed using the ABI PRISM 7700 Sequence Detector
(Applied Biosystems, Foster City, CA, USA). The samples were
amplified in 25ml reactions using a Taqman assay-on-demand
for CD31 (Mm00476702 and Mm01242575), CD9
(Mm01182917), GUS (b-glucuronidase; Mm00446953) from
Applied Biosystems and a 5T33MM-specific primer (forward
primer: 50-AAG-TTC-AAG-GGC-AAG-GCA-ACA-30 and reverse
primer: 50-CAG-GCT-GCT-GAG-CTG-CAT-G-30) and probe (50-
TGC-AGA-CAA-ATC-CTC-CAG-CAC-TGC-C-30) set located be-
tween the CDR2 and CDR3 region. The design was based on the
previously published sequence of the immunoglobulin heavy-
chain sequence expressed by the 5T33MM tumor cells.35 The
following conditions were used: 501C for 2 min and 951C for
10 min, followed by 40 cycles at 951C for 15 s and 601C for
1 min. The standard curve method was used to quantify the gene
expression of CD31, CD9 and 5T33MM idiotype relative to the
endogenous reference gene GUS.
Cultured cells (5 106) undergoing gene expression analysis
were lysed in 250ml of Trizol (Invitrogen, Carlsbad, CA, USA)
and maintained at 801C. Total RNA was extracted using the
Rneasy Mini kit (Qiagen, Valencia, CA, USA) as described by
the manufacturer. The concentration and purity of RNA were
determined by spectrophotometric measurement (Gene Quant
II; Pharmacia Biotech, Cambridge, UK). Two microgram of total
RNA was converted into cDNA by the superscript first-strand
synthesis system (Invitrogen) using random hexamers as primers.
Real-time Q-PCR was performed as described for the laser
microdissected samples; however, amplifying in a 50ml reac-
tion. Each sample was amplified in triplicate. The relative
standard curve method was used to quantitate the relative CD9
mRNA expression in myeloma cells. Relative standard curves
(50, 10, 2, 0.2 ng) were prepared for CD9 and b-glucoronidase
(GUS) using cDNA from 5TMM diseased BM.
Immunohistochemistry
The hind limbs from end-stage 5T33MM diseased mice were
dissected and fixed in Zn-fixative, decalcified in 15% ethylene-
diaminetetraacetic acid (EDTA) and embedded in paraffin as
described previously.36 The human bone biopsies from un-
treated newly diagnosed patients were fixed in formalin and
decalcified in formic acid before paraffin embedment. The use
of human bone biopsies was approved by the local ethical
committee. Series of adjacent sections were cut and subjected to
hematoxylin and eosin staining or processed for single/double-
immunostaining as follows: sections were deparaffinized in
xylene, washed in 99% ethanol, treated with 0.45% hydrogen
peroxide in 99% ethanol to inactivate endogenous peroxides
and rehydrated. Subsequently, the sections were demasked in
Tris/EDTA buffer (pH 9.0) for 10–14 h at 601C followed by
blocking with 0.5% casein in Tris-buffered saline and with a
biotin-blocking system (DakoCytomation, Glostrup, Denmark).
The single-immunostaining on mouse bones was performed by
incubating the sections with a rat anti-mouse CD9 antibody
(BD), which was detected by a biotin-labeled rabbit anti-rat IgG
antibody (DakoCytomation) followed by a step in horse radish
peroxidase (HRP)-conjugated streptavidin (DakoCytomation).
The detection was amplified by precipitation of biotin-
conjugated tyramide, followed by a reincubation with
HRP-conjugated streptavidin. The binding was visualized by
diaminobenzidine tetrahydrochloride (DAB)þ precipitation.
The double-immunostaining on human tissues was performed
in two steps: First, the sections were incubated with a mouse
anti-human CD9 (1:40, clone 72F6, Novocastra, Newcastle,
Upon Tyne, UK), which was detected with a polymer of
HRP-conjugated goat anti-mouse IgG antibodies (EnVision,
DakoCytomation) and visualized by DABþ (DakoCytomation).
Secondly, the sections were incubated with an FITC-labeled
mouse anti-human CD34 class II (1:100, clone QBEnd10,
Dako), which was detected with an alkaline phosphatase
(AP)-conjugated sheep anti-FITC FAB fragment (1:20, Roche)
and visualized by Fuchsinþ (DakoCytomation). Finally, the
sections were stained with hematoxylin and aqua mounted.
Transendothelial invasion assay
To assess the effect of the myeloma cell-BMEC interaction on
the myeloma cell invasiveness, invasion was evaluated in the
presence of a BM endothelial cell layer.
The transendothelial invasion assays for the MM5.1 and
5T33MMvv myeloma cells were conducted in a Transwell
migration system with a 8-mm pore size polyethylene (PET)
membrane (Elscolab, Kruibeke, Belgium). Before cell culture,
the upper face of the filters was coated with cold Matrigel (BD).
Next, BMEC (3 104) were plated onto the Matrigel-coated PET
membranes in the upper cell culture insert chamber and
cultured until confluence (48 h for STR-4 cells and 24 h for
4LHBMEC cells). Myeloma cells (105 for the MM5.1 cells and
2 105 for 5T33MMvv cells) suspended in 200 ml of serum free
RPMI-1640 medium were seeded in the upper compartment and
incubated for 24 h. As chemoattractant, we used RPMI-1640
medium with 20% FCI (300ml) in the lower compartment of the
invasion chamber. Cells that invaded the BMEC monolayer and
Matrigel were recovered from the lower compartment and
counted by flow cytometry. A known number of sphero blank
calibration beads were added as an internal standard (BD) for
quantification of the migrated myeloma cells. The migrated
myeloma cells were discriminated from potentially migrated EC
by their different forward/sideward scatter characteristics.
Percentage invading cells ¼
absolute number of cellsabsolute number of input beads
absolute number of beads
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To examine the role of CD9 in transendothelial invasion,
the myeloma cells (murine and human) were pre-treated with
either the neutralizing anti-mouse CD9 monoclonal antibody
KMC8 (10 mg/ml, BD, Mountain View, CA, USA)37–40 or the
neutralizing anti-human CD9 monoclonal antibody ALB6
(10 and 20 mg/ml; Immunotech, Marseille, France)41 or the
isotype-matched control antibody for 30 min. Antibodies were
also added to the lower compartment. Results are presented
as the percentage cell invasion compared with control invasion
in the absence of monoclonal antibody. In some experiments,
CD9 expression on the 5T33MMvv cells was investigated by
flow cytometric analysis before and after transendothelial
invasion.
Statistical analysis
For statistical analysis of the in vitro tests the Mann–Whitney
U-test was used. For the LMD experiments, we used the paired
Student’s t-test. Pp0.05 was considered significant.
Results
CD9 expression in the 5T33MM mouse model
To investigate CD9 expression in MM, we used the murine
model 5T33MM. Terminally diseased mice were killed and by a
double-flow cytometric staining procedure with CD9 and
tumor-specific anti-idiotype monoclonal antibodies, we demons-
trated CD9 expression on the 5T33MMvv (in vivo growing)
cell line at low levels (about 20% of the myeloma cells, range
18–32%) as shown by Figure 1a. To investigate CD9 expression
at the early stages of disease development, 5T33MMvv cells
obtained from terminally diseased mice were injected in naive
mice and CD9 expression was ascertained in the intermediate
stage by flow cytometry. As shown by Figure 1a, CD9
expression was detected on the majority of the myeloma cells
(70–75%).
We next determined CD9 expression on the stroma-indepen-
dent 5T33MMvt cell line. In contrast to the stroma-dependent
variant (5T33MMvv), this cell line was completely negative for
CD9 (Figure 1b). However, when these 5T33MMvt cells were
Figure 1 CD9 expression in the 5T33MM mouse model. (a and b) Flow cytometric analysis of the 5T33MM cells. Black filled histograms
represent the isotype control, and the gray line CD9 staining. CD9 staining is shown on gated anti-5T33MM–idiotype-positive cells. Results from
one representative experiment of three are shown. (a) Left: 5T33MMvv cells (exclusively in vivo growing) of terminally diseased mice; right:
5T33MMvv cells of intermediate-stage mice. (b) Left: the stroma independent 5T33MMvt cell line; middle: 5T33MMvtvv cells of quiescent/
intermediate-stage mice and right: recultured 5T33MMvtvv cells (5T33MMvtvvvt) cells. (c) Real-time Q-PCR analysis of the 5T33MM cells.
Relative fold induction of CD9 mRNA in the 5T33MMvt cells after in vivo passage (5T33MMvtvv cells, terminally diseased mice) and after
subsequent in vitro culturing (5T33MMvtvvvt cells) and 5T33MMvv cells of terminally diseased mice compared to 5T33MMvt cells (control) is
shown. The mean value7s.d. of three independent experiments is given.
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injected in young, naive mice (in vivo passage) and isolated in
the quiescent/intermediate stage, CD9 expression on the
obtained myeloma cells (now termed 5T33MMvtvv) reappeared
(Figure 1b). To confirm these data on RNA level by real-time
Q-PCR, myeloma cells from terminally diseased 5T33MMvtvv
and 5T33MMvv mice were isolated. In both 5T33MMvv and
5T33MMvtvv cells a distinct CD9 expression compared to the
5T33MMvt control cells (as shown in Figure 1c) was observed.
There was an equal amount of CD9 mRNA detected in
5T33MMvtvv and 5T33MMvv cells of terminally diseased mice.
These data indicate that the BM microenvironment most likely
induced expression of CD9 on the 5T33MMvt myeloma cells (in
vivo upregulation). Reculturing of 5T33MMvtvv cells for 14 days
resulted in the downregulation of CD9 (Figure 1b and c), further
confirming that the CD9 upregulation is dependent on the BM
microenvironment.
BMEC dependency of CD9 expression on the myeloma
cells
The BM microenvironment is a complex structure of various
extracellular components and many cell types, including
fibroblasts, endothelial cells, adipocytes, osteoblasts, osteo-
clasts, inflammatory cells, macrophages and hematopoietic
progenitors. As the BMECs are the first cell type the myeloma
cells encounter when homing to the BM, we investigated the
potential involvement of BMEC in the CD9 upregulation on the
myeloma cells. By real-time Q-PCR and flow cytometric
analysis, we compared CD9 expression of the 5T33MMvtvvvt
cells cultured with or without BMEC. Coculturing was
performed 14 days after the isolation of the cells, a time point
at which downregulation of CD9 had already started, as shown
in Figure 1b. After 5 days of coculturing with the BMEC, CD9
expression was distinctly upregulated compared to control cells
(Figure 2a). Moreover, we also observed a modest CD9
expression on the completely CD9-negative 5T33MMvt cells
after 5 days of coculture with BMEC (Figure 2b). These data
demonstrated that BMEC are at least one of the cell types
engaged in the BM microenvironmental modulated CD9
upregulation.
Quantitative expression of CD9 in 5T33MMvv BM
tissue specimens
To confirm the above data in situ, LMD and laser pressure
catapulting were performed on sections of bones from termi-
nally diseased 5T33MMvv mice, followed by real-time Q-PCR.
In preliminary experiments, immunostainings with the 5T33MM
idiotype-specific antibody and an antibody against CD31, a
marker for BMEC,36 revealed that the BM is packed with
myeloma cells and infiltrated with BMEC, as described,
previously.29 For LMD, BMECs were stained with CD31
immunofluorescence, and three separate zones were laser
dissected as follows (Figure 3a): (i) CD31-positive BMEC (EC),
(ii) myeloma cells in contact with BMEC (called ‘close’ in
Figure 3) and (iii) the myeloma cells more than five cell layers
away from the BMEC (called ‘away’ in Figure 3). In preliminary
experiments, the RNA quality was checked after the cutting and
staining steps, and proved to be high (data not shown). Real-time
Q-PCR revealed a predominant CD9 expression in myeloma
cells in contact with the BMEC (close) compared to more distant
positioned myeloma cells (away) as shown in Figure 3b. This
differential expression was consistent within the four mice
analyzed (Figure 3), and also consistent within different LMD
preparations from the same mice (data not shown). The nature of
the microdissected cells was verified by real-time Q-PCR by
amplifying the 5T33MM idiotype-specific Ig heavy-chain gene
and the BMEC marker CD31 (Figure 3b). The 5T33MM idiotype
gene was expressed at equal levels in the myeloma cells
microdissected close to and away from BMEC, demonstrating an
equal purity of myeloma cells in the preparations irrespective of
their proximity to BMEC. The level of CD31 expression in the
myeloma cell preparations was not affected by how close they
were to BMEC when microdissected. Thus, there is no evidence
Figure 2 Induced CD9 expression on 5T33MMvtvvvt and 5T33MMvt
cells after direct contact with BM endothelial cells. (a and b, upper
panel) Real-time Q-PCR analysis showing relative fold induction of
CD9 mRNA in myeloma cells after 5 days of coculturing with the
BMEC cell line STR-4 compared to control. The mean value7s.d. of
three independent experiments is given. (Lower panel) Flow cyto-
metric analysis showing induced CD9 expression on the surface of
myeloma cells after 5 days of coculturing with the BMEC compared to
control. The black filled histogram is the isotype control, and the gray
line CD9 staining. The CD9 staining is shown on gated anti-5T33MM
–idiotype-positive cells. One experiment representative of three is
shown. (a) 5T33MMvtvvvt cells (14 days after culturing) before and
after coculture. (b) 5T33MMvt cells before and after coculture.
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for increased contamination of myeloma cells by BMEC, when
they are microdissected from sites close to BMEC. Furthermore,
these myeloma cell preparations showed on average a 10 times
lower expression of CD31, compared to the BMEC preparations.
To rule out the possibility that this differential CD9 expression
might be owing to difference in oxygen tension, 5T33MMvt cells
were incubated under hypoxic conditions (1% oxygen) for 24 h
at 371C. Subsequent real-time Q-PCR showed no difference in
CD9 expression in cells cultured in hypoxic conditions
compared to normoxia (20% oxygen), whereas the vascular
epidermal growth factor gene, known to be upregulated at
hypoxic conditions42 was (data not shown). To rule out the
possibility that the differential expression might be owing to
RNA contamination of pericytes, the presence of pericytes
between the BMEC and myeloma cells was investigated. By
actin staining we confirmed the absence of pericytes (data not
shown).
Immunolocalization of CD9 in BM biopsies from
5T33MMvv diseased mice and human myeloma
patients
To confirm at the positioning level the in situ data obtained by
real-time Q-PCR analysis of laser-microdissected cells, we
performed immunohistochemical stainings for CD9. The im-
munostainings on bone sections from the end-stage 5T33MMvv
diseased mice, revealed a distinct immunolocalization of CD9
in some of the myeloma cells next to the BMEC, whereas more
distant myeloma cells were negative for CD9, as shown in two
different 5T33MMvv mice (Figure 4a and b). The BMEC were
also observed positive for CD9 (Figure 4a and b).
To assess the relevance of CD9 to myeloma patients, we
performed immunostainings for CD9 in combination with the
detection of CD34 class II (classical BMEC marker) on sections
of 30 different BM biopsies from newly diagnosed myeloma
patients. Here we observed CD9 immunoreactivity in myeloma
cells in 70% (21 of 30) of the biopsies. If considering only the
biopsies with interstitial distribution of MM cells, 80% of them
(20 of 25) were partially positive for CD9. In the latter, 85% (17
of 20) showed the CD9-positive MM cells positioned mainly in
the neighborhood of the CD34þ BMEC, whereas MM cells
more distant from the BMECs were negative for CD9 (Figure 4c
and d). This observation is consistent with observations from
5T33MM mice. Only two of six biopsies having a nodular MM
cell distribution and two of nine biopsies having a packed MM
marrow showed a local CD9 expression in a few MM cells.
Interestingly, the latter had all a direct contact with BMEC
(Figure 4e). The majority of the MM cells in nodular and packed
distributions are negative for CD9 (Figure 4f). In contrast with
the immunostainings on the 5T33MMvv diseased mice, the
BMECs in the human biopsies were always negative for CD9.
Megakaryocytes, from which CD9 originally was cloned,43 were
used as positive controls for CD9 in the sections where MM cells
and BMECs were negative.
Role of CD9 in transendothelial cell invasion of murine
5T33MMvv and human MM5.1 myeloma cells
To investigate the role of CD9 in transendothelial invasion of
the myeloma cells, transendothelial invasion assays were
performed. By flow cytometric analysis, we demonstrated
that about 75% of the transendothelial-invaded 5T33MMvv
Figure 3 LMD reveals an induced expression of CD9 in 5T33MMvv cells adjacent to BMEC. (a) Illustrates the laser microdissected cells as they
appear in the CD31-stained histological section, during the different steps of the procedure.(a1) Immunofluorescence stained section; (a2) the
respective areas with CD31-positive BMEC (red), the myeloma cells close/adjacent to BMEC (green) and the myeloma cells further away from the
BMEC (blue) are selected; (a3) the BMEC are first microdissected (asterisk) to prevent contamination of the myeloma preparation; (a4) the two
different myeloma cells areas (green: asterisk and blue: double asterisks) are subsequently microdissected into separate tubes. The catapulting of
the microdissected cells leaves behind craters in the glass slide. Original magnification 20. (b) Real-time Q-PCR analysis of the isolated
5T33MMvv cells away or in close contact with BMEC reveals a fivefold induction of CD9 mRNA in the myeloma cells in close contact with BMEC
compared to the myeloma cells further away from BMEC. The mean value7s.d. of experiments performed on four different animals is given. The
origin of the microdissected cells was confirmed by real-time Q-PCR analysis for the 5T33MM idiotype expression and CD31 expression.
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myeloma cells expressed CD9 compared to only 20% CD9
expression before transendothelial invasion (Figure 5a). These
data suggest the involvement of CD9 in this process.
To further investigate the role of CD9 in transendothelial
invasion of the myeloma cells, transendothelial invasion assays
were performed in which CD9-expressing murine 5T33MMvv
cells were incubated with the monoclonal anti-CD9-neutraliz-
ing antibody KMC8. The invasion in the negative control was
between 5 and 8%. Maximal invasion was 20–25%. As shown
in Figure 5b, KMC8 significantly inhibited transendothelial
invasion of the myeloma cells by about 47% at a concentration
of 10 mg/ml (range 43–51%) as compared with the invasion in
the absence of monoclonal antibody or in the presence of
irrelevant isotype antibody. No further inhibition was observed
when increasing the concentration of KMC8 to 15 or 20mg/ml.
The data indicate that CD9 indeed is involved in transendo-
thelial invasion.
Next, to confirm these data for the human condition the
human stroma-dependent MM5.1 and stroma-independent
MM5.2 myeloma cells were screened by flow cytometric
analysis for CD9 expression, as these cell lines resemble the
murine situation (5T33MMvv versus 5T33MMvt) as closely as
possible. Flow cytometric analysis showed strong CD9 expres-
sion on the MM5.1 myeloma cells, whereas the MM5.2 cells
were CD9 negative (data not shown). The involvement of CD9
in transendothelial invasion was also confirmed when using the
MM5.1 cell line and the human monoclonal anti-CD9-
neutralizing antibody ALB6. The invasion in the negative
control was between 2 and 5%. Maximal invasion was 15–
20%. ALB6 significantly inhibited transendothelial invasion of
the myeloma cells by about 29% at 10mg/ml (range 25–31%)
Figure 4 Immunohistochemistry confirms an induced expression of
CD9 in myeloma cells adjacent to BMEC. (a and b) Longitudinal
sections of bones from two different terminal diseased 5T33MMvv
mice immunostained for CD9 (brown), showing a distinct expression
in some of the myeloma cells (arrowhead) adjacent to the BMEC,
whereas more distant myeloma cells show a weak to no expression
of CD9 (asterisks). The BMECs were also positive for CD9.
(c–f) Illustrated the immunolocalization of CD9 (brown) and CD34
(red) in bone biopsies from newly diagnosed MM patients. (c and d)
A distinct expression of CD9 in some of myeloma cells having an
interstitial distribution (arrowhead) positioned in the vicinity of BMEC,
whereas more distant interstitial distributed myeloma cells show a
weak to no expression of CD9 (asterisks). Human BMECs show no
expression of CD9. (e) At rare occasions, the myeloma cells having a
nodular positioning express CD9 (arrowhead), which were only
observed in the vicinity of BMEC. The remaining myeloma cells show
a weak to no expression of CD9 (asterisks). (f) Packed myeloma cells
showing no expression of CD9. Bars are 25mm.
Figure 5 Role of CD9 in the transendothelial invasion of murine
5T33MMvv and human MM5.1 myeloma cells. (a) CD9 expression of
the 5T33MMvv cells before and after the transendothelial invasion.
The black filled histogram is the isotype control, the dashed line CD9
staining before invasion, and the gray line CD9 staining after invasion.
The CD9 staining is shown on gated anti-idiotype-positive cells.
Results from one representative experiment of three are shown.
(b) Effect of the anti-CD9-neutralizing monoclonal antibody KMC8 on
the transendothelial invasion of the CD9-expressing murine
5T33MMvv cells. Experiments were performed in triplicate and results
are represented as the percentage invasion compared to control
invasion in the absence of monoclonal antibody (mean value7s.d.).
(c) Effect of the anti-CD9 neutralizing monoclonal antibody ALB6 on
the transendothelial invasion of the CD9 expressing human MM5.1
cells. Experiments were performed in triplicate and results are given as
the percentage invasion compared to control invasion in the absence
of monoclonal antibody (mean value7s.d.).
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and 48% at 20mg/ml (range 42–54%) as compared with the
invasion in the absence of monoclonal antibody or in the
presence of irrelevant isotype antibody (Figure 5c). Again, these
data indicate involvement of CD9 in transendothelial invasion.
Discussion
Despite intensive research and emerging therapies in the past
few years, MM still remains an incurable malignancy. One of
the characteristics is the predominant localization of the
myeloma cells in the BM. This restricted presence is most likely
owing to the combination of selective homing and subsequent
selective survival of the myeloma cells in the BM.28 Homing of
the myeloma cells is thus an essential event in the disease
development. This process is mediated by chemokines, adhe-
sion molecules and proteases.6 CD9 has been described to be
involved in the regulation of cellular processes considered
relevant for malignant conversion like migration and inva-
sion.7,12,24 Accordingly, CD9 expression levels were found to
correlate inversely with tumor progression in several malignant
diseases.15–19 Based on these reports, it was assumed that low
levels of CD9 expression could thus be one of the promoting
steps of cancer progression and might thus have high prognostic
value. However, recent reports questioned the reliability of CD9
expression in assessing prognosis of breast cancer and human
osteosarcoma.22,23 Moreover, recently it was demonstrated by
Sauer et al.24 that in cervical carcinoma CD9 expression is
downregulated during tumor progression to promote expansion
of the malignant cells, but on the other hand is also locally re-
expressed to adjust to microenvironmental requirements. They
propose that cells with low CD9 expression are responsible for
tumor growth, but only those cells able to upregulate CD9 can
enter the blood circulation during further tumor progression.
The 5T33MM model is a good model to test this hypothesis, as
by in vivo transplantation, the expression of CD9 during the
course of the disease can be followed.29
In the present study, we found by flow cytometric analysis a
low CD9 expression on the surface of 5T33MMvv myeloma
cells of terminally diseased mice, whereas the stroma-indepen-
dent variant 5T33MMvt cell line did not express CD9. To
analyze whether the BM microenvironment was engaged in the
regulation of this differential CD9 expression, 5T33MMvt cells
were injected in naive mice, isolated in the quiescent/
intermediate stage (5T33MMvtvv cells) and were now found to
express CD9. As reported previously, three phases can be
distinguished during 5TMM tumorigenesis: a quiescent stage of
slow tumor progression, an intermediate stage of moderate
tumor progression and an end stage with accelerated progres-
sion.44 However, after in vitro culturing of the 5T33MMvtvv
cells, CD9 expression was again downregulated, suggesting that
tumor–stroma interactions are involved in the CD9 upregulation
in vivo. These data were confirmed by the upregulation of CD9
after injecting low CD9-expressing 5T33MMvv end-stage
myeloma cells in naive mice. These data clearly demonstrated
that in the early disease stages, the BM microenvironment
induces expression of CD9 in the 5T33MM cells.
Based on the fact that the BMEC are the first cell type the
myeloma cells come across when homing to the BM and based
on the recent publication reporting CD9 re-expression on
carcinoma cells in process of invading blood and lymphatic
vessels,24 the involvement of BMEC in the CD9 expression on
the myeloma cells was assessed. BMECs were able to partially
retrieve CD9 expression on the 5T33MMvtvvvt and 5T33MMvt
cells. The difference between both cell lines concerning the
extent of the retrieval of CD9 expression might be explained by
difference in hypermethylation of the CD9 promoter. Indeed,
variegated methylation patterns, even in clonally derived cell
populations, as well as environment and stage-dependent levels
of methylation have been reported.26,45 In human cells, flow
cytometric analysis showed very low CD9 expression on the
stroma-independent growing MM5.2 myeloma cells (data not
shown). However, after coculturing with the human BMEC
4LHBMEC cell line CD9 expression was again partially retrieved
(data not shown). These data suggest that BMEC are, at least
partially, responsible for the in vivo upregulation of CD9.
Furthermore, using real-time Q-PCR on myeloma cells isolated
in situ by LMD, we demonstrated reproducibly a predominant
CD9 expression on the myeloma cells in contact with the BMEC
in comparison to those myeloma cells more distant from BMEC.
In contrast, control genes were expressed at similar levels at
these respective areas. To our knowledge, we are the first to use
LMD to assess microenvironmental effects on myeloma cells.
Immunohistochemistry allowed confirming of these findings at
the protein level and, furthermore, showed that not all MM cells
in contact with BMEC are CD9 positive. This differential
expression may relate to different contact times with BMEC,
and is compatible with a transient upregulation of CD9. The
immunostainings in the human biopsies showed the relevance
of these observations to patients, and documented even more so
the importance of the myeloma cell microenvironment for CD9
expression. There is indeed a big contrast between the high CD9
expression of myeloma cells in the interstitial configuration,
which favors heterotypic cell interactions, and the low CD9
expression when they are in nodular or packed configuration,
where heterotypic interactions are rare. In the latter configura-
tions, the importance of the microenvironment is further
documented by the fact that myeloma cells expressing CD9
are rare and only seen at the vicinity of endothelial cells.
Our group has already reported BMEC-dependent upregula-
tion of MMP931 and insulin like growth factor (IGF)-1R46 in the
5T33MMvt cells, which are involved in the homing of the
myeloma cells. As CD9 has been described to be involved in the
cell adhesion, migration and invasion, we investigated the role
of CD9 in transendothelial invasion. The majority of the
transendothelial invading murine myeloma cells expressed
CD9, suggesting that CD9 indeed might be involved in this
process (either by upregulation of expression or by selective
migration). Neutralizing anti-CD9 monoclonal antibodies sig-
nificantly inhibited transendothelial invasion of the CD9
expressing human MM5.1 and murine 5T33MMvv cell line,
again confirming CD9 involvement in homing. Recently, Longo
et al.47 also provided evidence for a role of CD9 in tumor–
endothelial cell interaction and vascular dissemination in
melanoma by in vitro studies of transendothelial migration,
which was significantly blocked by treatment with monoclonal
anti-CD9 antibodies.
Our data thus confirm and extend the work reported by Sauer
et al.24 We thus postulate that as myeloma cells encounter
BMEC, CD9 becomes upregulated making them able to pass the
endothelial barrier, either to enter the extravascular compart-
ment of the BM or to enter the vasculature, necessary for the
spreading of the myeloma cells to anatomically distant BM sites
or extramedullary sites at the end stage of the disease. There is a
significant increased microvessel density (MVD) in myeloma-
invaded BM compared to non-invaded BM.36 During myeloma
progression, the increase in tumor load is however more
extensive than the increased microvessel density in the BM.
Moreover, the size and perimeter of the microvessels decreases
during myeloma progression.30 Both observations result in an
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increase in the proportion of myeloma cells to BMEC during
myeloma progression. As such, as disease progresses, the
percentage of myeloma cells in contact with BMEC declines,
leading to a reduced number of myeloma cells that express
CD9. The recent observation that clonal PC from MM patients
show significantly reduced CD9 expression as compared to PC
from MGUS patients confirm our data.25
In conclusion, our results demonstrate an upregulation of
CD9 expression in the myeloma cells in early disease stage in
vivo by the interaction of the myeloma cells with the BMEC.
Moreover, in terminally diseased 5T33MMvv mice and newly
diagnosed patients, we demonstrate a strong local expression of
CD9 on myeloma cells in contact with BMEC. We also provide
evidence that CD9 is involved in transendothelial invasion, thus
possibly mediating homing and/or spreading of the myeloma
cells.
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